Summary

High levels of LDL cholesterol and triglycerides, which are types of blood fats, are major contributors to atherosclerotic cardiovascular disease. Gene-editing technologies offer a potential alternative to lipid-lowering medications. In a new CRISPR experiment, a single infusion of a gene-editing treatment kept triglyceride levels low in monkeys for three years. The findings support the possibility of controlling blood fats with a lasting DNA change, potentially replacing daily doses of medication.

AI summaries can be wrong sometimes—always verify important details using the source article.